Youssef Mandour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Youssef Mandour has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Abdelmageed
Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publications - Mark Messak
Faculty of Medicine, Helwan University, Helwan, Egypt
3 shared publications - Ahmed Negida
Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA
2 shared publications - Youssef A. Khattab
Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 shared publications - Abdullah Emad Shabeeb
Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication - Abdulrahman M. Zakaria
Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication
Latest Publications
- 30 May 2026
- Published by Taylor & Francis in Neurodegenerative Disease Management
- p. 1-16
Bright light therapy for depression and excessive daytime sleepiness in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression
Non-motor symptoms, including depression and excessive daytime sleepiness (EDS), reduce quality of life in Parkinson's disease (PD). Pharmacological treatments may cause side-effects, highlighting the need for non-pharmacological approaches. We conducted an updated meta-analysis with linear and non-linear dose-response meta-regression to evaluate bright light therapy (BLT) on depression and EDS in PD. PubMed, Scopus, and WOS were systematically searched through September 2025. Risk of bias was assessed using RoB-2 and NIH single-arm tools. Mean difference (MD) or standardized mean difference (SMD) with 95%confidence intervals (CI) were pooled using fixed-effects models. Linear and non-linear dose-response meta-regressions were performed. Eight studies were identified, six included in meta-analysis. For EDS, five studies (n = 159) showed no significant effect of BLT (MD =-1.14, 95%CI [-2.43, 0.15], p = 0.083, I2 = 0%), with no linear (p = 0.78) or non-linear (p = 0.97) dose-response relationship. For depression, five studies (n = 194) also showed no significant effect (SMD =-0.13, 95%CI [-0.41, 0.16], p = 0.38, I2 = 0%), without linear (p = 0.82) or non-linear (p = 0.85) associations. Sensitivity analyses were consistent. BLT was not associated with significant improvement in depression or EDS in PD, and no dose-response relationship was identified. Given methodological limitations, BLT cannot currently be recommended for clinical use. Future standardized dose-finding trials stratified by disease stage and retinal/ipRGC integrity are needed.
- 30 May 2026
- Published by Taylor & Francis in Neurodegenerative Disease Management
- p. 1-16
Bright light therapy for depression and excessive daytime sleepiness in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression
Non-motor symptoms, including depression and excessive daytime sleepiness (EDS), reduce quality of life in Parkinson's disease (PD). Pharmacological treatments may cause side-effects, highlighting the need for non-pharmacological approaches. We conducted an updated meta-analysis with linear and non-linear dose-response meta-regression to evaluate bright light therapy (BLT) on depression and EDS in PD. PubMed, Scopus, and WOS were systematically searched through September 2025. Risk of bias was assessed using RoB-2 and NIH single-arm tools. Mean difference (MD) or standardized mean difference (SMD) with 95%confidence intervals (CI) were pooled using fixed-effects models. Linear and non-linear dose-response meta-regressions were performed. Eight studies were identified, six included in meta-analysis. For EDS, five studies (n = 159) showed no significant effect of BLT (MD =-1.14, 95%CI [-2.43, 0.15], p = 0.083, I2 = 0%), with no linear (p = 0.78) or non-linear (p = 0.97) dose-response relationship. For depression, five studies (n = 194) also showed no significant effect (SMD =-0.13, 95%CI [-0.41, 0.16], p = 0.38, I2 = 0%), without linear (p = 0.82) or non-linear (p = 0.85) associations. Sensitivity analyses were consistent. BLT was not associated with significant improvement in depression or EDS in PD, and no dose-response relationship was identified. Given methodological limitations, BLT cannot currently be recommended for clinical use. Future standardized dose-finding trials stratified by disease stage and retinal/ipRGC integrity are needed.
- 15 May 2026
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 126 (6) , 1947-1966
Therapeutic effects of cannabinoids on Parkinson’s disease: an updated systematic review and meta-analysis of randomized controlled trials
Current treatments for Parkinson's disease (PD) are primarily symptomatic and may lead to motor fluctuations and levodopa-induced dyskinesia over time, highlighting the need to repurpose other medications. Cannabinoids have gained attention as potential repurposed treatments. This systematic review and meta-analysis evaluated their efficacy in PD while addressing limitations of previous reviews, including low statistical power and inclusion of cannabinoid antagonists in pooled analyses. A literature search was conducted through PubMed, Scopus, and Web of Science, identifying randomized controlled trials (RCTs) evaluating the use of cannabinoids in PD. Quality assessment was done via RoB-2. A random-effects meta-analysis was performed using the meta and metafor packages in R, with mean differences (MD) or standardized mean differences (SMD; Hedges' g) reported with 95% confidence interval (CI). A sensitivity analysis was carried out to assess the robustness of our findings. In crossover trials, effect sizes and standard errors were extrapolated from the reported CIs, considering the paired design. Eleven RCTs were identified, six of which were eligible for meta-analysis due to the absence of poolable outcomes in the remainder. Cannabinoids did not significantly improve PD severity (SMD = 0.16, 95% CI[-0.13 to 0.44], p = 0.27, I²=0%), motor examination (SMD=-0.08, 95% CI[-0.35 to 0.20], p = 0.57, I²=0%), motor experiences of daily living (SMD=-0.08, 95% CI[-0.49 to 0.33], p = 0.71, I²=0%), non-motor symptoms (SMD= -0.03, 95% CI[-0.72 to 0.67], p = 0.94, I²= 64.3%). Sensitivity analysis excluding Peball et al. showed that the pooled estimate of non-motor symptoms was largely driven by nabilone (SMD = 0.34, 95%CI [-0.19 to 0.88], p = 0.21, I²=0%), suggesting a drug-specific benefit signal. Cannabinoids have not shown significant benefit in PD; however, our findings should be interpreted with caution. The nabilone benefit signal for non-motor symptoms represents a distinct question warranting dedicated trials. Future studies should use standardized, pharmacologically stratified protocols.
- 15 May 2026
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 126 (6) , 1947-1966
Therapeutic effects of cannabinoids on Parkinson’s disease: an updated systematic review and meta-analysis of randomized controlled trials
Current treatments for Parkinson's disease (PD) are primarily symptomatic and may lead to motor fluctuations and levodopa-induced dyskinesia over time, highlighting the need to repurpose other medications. Cannabinoids have gained attention as potential repurposed treatments. This systematic review and meta-analysis evaluated their efficacy in PD while addressing limitations of previous reviews, including low statistical power and inclusion of cannabinoid antagonists in pooled analyses. A literature search was conducted through PubMed, Scopus, and Web of Science, identifying randomized controlled trials (RCTs) evaluating the use of cannabinoids in PD. Quality assessment was done via RoB-2. A random-effects meta-analysis was performed using the meta and metafor packages in R, with mean differences (MD) or standardized mean differences (SMD; Hedges' g) reported with 95% confidence interval (CI). A sensitivity analysis was carried out to assess the robustness of our findings. In crossover trials, effect sizes and standard errors were extrapolated from the reported CIs, considering the paired design. Eleven RCTs were identified, six of which were eligible for meta-analysis due to the absence of poolable outcomes in the remainder. Cannabinoids did not significantly improve PD severity (SMD = 0.16, 95% CI[-0.13 to 0.44], p = 0.27, I²=0%), motor examination (SMD=-0.08, 95% CI[-0.35 to 0.20], p = 0.57, I²=0%), motor experiences of daily living (SMD=-0.08, 95% CI[-0.49 to 0.33], p = 0.71, I²=0%), non-motor symptoms (SMD= -0.03, 95% CI[-0.72 to 0.67], p = 0.94, I²= 64.3%). Sensitivity analysis excluding Peball et al. showed that the pooled estimate of non-motor symptoms was largely driven by nabilone (SMD = 0.34, 95%CI [-0.19 to 0.88], p = 0.21, I²=0%), suggesting a drug-specific benefit signal. Cannabinoids have not shown significant benefit in PD; however, our findings should be interpreted with caution. The nabilone benefit signal for non-motor symptoms represents a distinct question warranting dedicated trials. Future studies should use standardized, pharmacologically stratified protocols.
- Top Cited PapersOpen Access
- 9 March 2026
- Published by Springer Nature in Advances in Health Sciences Education
- p. 1-27
The impostor phenomenon construct in medical education: a meta-analysis of its prevalence and a critical appraisal of its measurement
Impostor phenomenon (IP) is widely cited as a significant challenge in medical education, yet its conceptual and methodological foundations are unstable, hindering a clear understanding of its true scope and impact. Thus, this systematic review and meta-analysis aimed to first establish a pooled prevalence of IP among medical students, and second, to critically appraise the measurement tools and definitions used in the literature. We systematically searched PubMed, Scopus, Web of Science, and CINAHL through July 2025 for all studies quantitatively assessing IP prevalence in medical students. Using a random-effects model, we analyzed data from 34 studies, including 9,550 participants. The overall pooled prevalence of IP was 49% (95% CI [0.43–0.54]), but this figure is complicated by extreme heterogeneity across studies (I 2 =95.6%, P < 0.001) despite multiple sensitivity analyses. Subgroup analyses revealed significant prevalence differences by gender (females 51% vs. males 40%; P = 0.021), geographic region ( P < 0.001), and the measurement tool used ( P < 0.001). The qualitative synthesis suggested associations between IP and negative mental health outcomes, including anxiety, depression, and burnout. Nevertheless, the variance driven by different measurement tools suggests that researchers may not be consistently measuring the same construct. The reliance on unvalidated cutoffs further weakens the validity of prevalence estimates. We conclude that while IP is clearly a prevalent concern, the construct’s weak theoretical grounding and inconsistent measurement impede meaningful progress. Advancing this area of medical education research requires a foundational shift toward conceptual clarity and methodological rigor.
- 9 March 2026
- Published by Springer Nature in Advances in Health Sciences Education
- p. 1-27
Top Cited PapersOpen AccessThe impostor phenomenon construct in medical education: a meta-analysis of its prevalence and a critical appraisal of its measurement
Impostor phenomenon (IP) is widely cited as a significant challenge in medical education, yet its conceptual and methodological foundations are unstable, hindering a clear understanding of its true scope and impact. Thus, this systematic review and meta-analysis aimed to first establish a pooled prevalence of IP among medical students, and second, to critically appraise the measurement tools and definitions used in the literature. We systematically searched PubMed, Scopus, Web of Science, and CINAHL through July 2025 for all studies quantitatively assessing IP prevalence in medical students. Using a random-effects model, we analyzed data from 34 studies, including 9,550 participants. The overall pooled prevalence of IP was 49% (95% CI [0.43–0.54]), but this figure is complicated by extreme heterogeneity across studies (I 2 =95.6%, P < 0.001) despite multiple sensitivity analyses. Subgroup analyses revealed significant prevalence differences by gender (females 51% vs. males 40%; P = 0.021), geographic region ( P < 0.001), and the measurement tool used ( P < 0.001). The qualitative synthesis suggested associations between IP and negative mental health outcomes, including anxiety, depression, and burnout. Nevertheless, the variance driven by different measurement tools suggests that researchers may not be consistently measuring the same construct. The reliance on unvalidated cutoffs further weakens the validity of prevalence estimates. We conclude that while IP is clearly a prevalent concern, the construct’s weak theoretical grounding and inconsistent measurement impede meaningful progress. Advancing this area of medical education research requires a foundational shift toward conceptual clarity and methodological rigor.